Frequency of the TMPRSS2:ERG Gene Fusion is Increased in Moderate to Poorly Differentiated Prostate Cancers

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2007 Jan 30

PMID 17259299

Citations 81

Authors

Ashish B Rajput

Melinda A Miller

Alessandro De Luca

Niki Boyd

Sam Leung

Antonio Hurtado-Coll

Ladan Fazli

Edward C Jones

Jodie B Palmer

Martin E Gleave

Michael E Cox

David G Huntsman

Affiliations

Soon will be listed here.

Abstract

Background: Recent reports indicate that prostate cancers (CaP) frequently over-express the potential oncogenes, ERG or ETV1. Many cases have chromosomal rearrangements leading to the fusion of the 5' end of the androgen-regulated serine protease TMPRSS2 (21q22.2) to the 3' end of either ERG (21q22.3) or ETV1 (7p21.3). The consequence of these rearrangements is aberrant androgen receptor-driven expression of the potential oncogenes, ETV1 or ERG.

Aim: To determine the frequency of rearrangements involving TMPRSS2, ERG, or ETV1 genes in CaP of varying Gleason grades through fluorescence in situ hybridisation (FISH) on CaP tissue microarrays (TMAs).

Methods: Two independent assays, a TMPRSS2 break-apart assay and a three-colour gene fusion FISH assay were applied to TMAs. FISH positive cases were confirmed by reverse transcriptase (RT) PCR and DNA sequence analysis.

Results: A total of 106/196 (54.1%) cases were analysed by FISH. None of the five benign prostatic hyperplasia cases analysed exhibited these gene rearrangements. TMPRSS2:ERG fusion was found more frequently in moderate to poorly differentiated tumours (35/86, 40.7%) than in well differentiated tumours (1/15, 6.7%, p = 0.017). TMPRSS2:ETV1 gene fusions were not detected in any of the cases tested. TMPRSS2:ERG fusion product was verified by RT-PCR followed by DNA sequencing in 7/7 randomly selected positive cases analysed.

Conclusion: This study indicates that TMPRSS2:ERG gene rearrangements in CaP may be used as a diagnostic tool to identify prognostically relevant sub-classifications of these cancers.

Citing Articles

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer.

Maylin Z, Smith C, Classen A, Asim M, Pandha H, Wang Y Cells. 2024; 13(23).

PMID: 39682746 PMC: 11639977. DOI: 10.3390/cells13231999.

Alternative splicing in prostate cancer progression and therapeutic resistance.

Rawat C, Heemers H Oncogene. 2024; 43(22):1655-1668.

PMID: 38658776 PMC: 11136669. DOI: 10.1038/s41388-024-03036-x.

Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.

Maekawa S, Takata R, Obara W Cancers (Basel). 2024; 16(3).

PMID: 38339274 PMC: 10854717. DOI: 10.3390/cancers16030523.

Relationship between endogenous testosterone and prostate carcinoma.

Paunikar V, Barapatre S J Family Med Prim Care. 2022; 11(7):3735-3739.

PMID: 36387691 PMC: 9648326. DOI: 10.4103/jfmpc.jfmpc_2349_21.

The evolving landscape of prostate cancer somatic mutations.

Cotter K, Rubin M Prostate. 2022; 82 Suppl 1:S13-S24.

PMID: 35657155 PMC: 9328313. DOI: 10.1002/pros.24353.

References

Mastrangelo T, Modena P, Tornielli S, Bullrich F, Testi M, Mezzelani A . A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene. 2000; 19(33):3799-804. DOI: 10.1038/sj.onc.1203762. View

Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim R . TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006; 66(21):10242-6. DOI: 10.1158/0008-5472.CAN-06-1986. View

Gavrilov D, Kenzior O, Evans M, Calaluce R, Folk W . Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer. 2001; 37(8):1033-40. DOI: 10.1016/s0959-8049(01)00077-6. View

Vaarala M, Porvari K, KYLLONEN A, Lukkarinen O, Vihko P . The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer. 2001; 94(5):705-10. DOI: 10.1002/ijc.1526. View

Dong J . Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 2002; 20(3-4):173-93. DOI: 10.1023/a:1015575125780. View

Brothman A . Cytogenetics and molecular genetics of cancer of the prostate. Am J Med Genet. 2002; 115(3):150-6. DOI: 10.1002/ajmg.10694. View

Oikawa T, Yamada T . Molecular biology of the Ets family of transcription factors. Gene. 2003; 303:11-34. DOI: 10.1016/s0378-1119(02)01156-3. View

Fritsch M, Bridge J, Schuster A, Perlman E, Argani P . Performance characteristics of a reverse transcriptase-polymerase chain reaction assay for the detection of tumor-specific fusion transcripts from archival tissue. Pediatr Dev Pathol. 2002; 6(1):43-53. DOI: 10.1007/s10024-002-0013-1. View

Makretsov N, He M, Hayes M, Chia S, Horsman D, Sorensen P . A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer. 2004; 40(2):152-7. DOI: 10.1002/gcc.20028. View

10.

Hermans K, van Marion R, van Dekken H, Jenster G, van Weerden W, Trapman J . TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006; 66(22):10658-63. DOI: 10.1158/0008-5472.CAN-06-1871. View

11.

Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster C . Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2006; 26(18):2667-73. DOI: 10.1038/sj.onc.1210070. View

12.

Tomlins S, Laxman B, Dhanasekaran S, Helgeson B, Cao X, Morris D . Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007; 448(7153):595-9. DOI: 10.1038/nature06024. View

13.

Arora R, Koch M, Eble J, Ulbright T, Li L, Cheng L . Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004; 100(11):2362-6. DOI: 10.1002/cncr.20243. View

14.

Stamey T, Caldwell M, McNeal J, Nolley R, Hemenez M, Downs J . The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol. 2004; 172(4 Pt 1):1297-301. DOI: 10.1097/01.ju.0000139993.51181.5d. View

15.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L . Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 2004; 64(18):6595-602. DOI: 10.1158/0008-5472.CAN-03-3998. View

16.

Brothman A, Maxwell T, Cui J, Deubler D, Zhu X . Chromosomal clues to the development of prostate tumors. Prostate. 1999; 38(4):303-12. DOI: 10.1002/(sici)1097-0045(19990301)38:4<303::aid-pros6>3.0.co;2-e. View

17.

Nupponen N, Visakorpi T . Molecular biology of progression of prostate cancer. Eur Urol. 1999; 35(5-6):351-4. DOI: 10.1159/000019907. View

18.

Krueckl S, Sikes R, Edlund N, Bell R, Hurtado-Coll A, Fazli L . Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res. 2004; 64(23):8620-9. DOI: 10.1158/0008-5472.CAN-04-2446. View

19.

Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Furasato B, Sun C . Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005; 24(23):3847-52. DOI: 10.1038/sj.onc.1208518. View

20.

Tomlins S, Rhodes D, Perner S, Dhanasekaran S, Mehra R, Sun X . Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310(5748):644-8. DOI: 10.1126/science.1117679. View